Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722692 · ClinicalTrials.gov registry record · Phase 3
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
A Phase 3 study of Breast Cancer and Breast Neoplasms, sponsored by Uppsala University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 9
- Study locations
NCT04722692 is a Phase 3 study of Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Uppsala University. The registered enrollment target is 500 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT04722692, a Phase 3 study of Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Uppsala University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 9
- Study locations
Study Summary
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to patients with a preoperative diagnosis of ductal cancer in situ of the breast (DCIS), an unclear BIRADS 4-5 planned for diagnostic excision or women planned for risk reducing mastectomy. SPIO is injected in the primary operation, and should final specimen pathology demonstrate invasive breast cancer, only then is an operation in the axilla (d-SLND) performed.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Delayed SLND
- DIAGNOSTIC_TEST Late SLND
Study Locations (9)
Other
- The University of Hong Kong-Shenzhen Hospital - Hong Kong
- Uppsala University Hospital - Uppsala
Texas
- Baylor College Of Medicine - Houston
Dalarna County
- Falun Lasarett - Falun
Kronoberg County
- Växjö County Hospital - Vaxjo
Skåne County
- Skåne University Hospital - Lund
Västmanland County
- Västmanland County Hospital - Västerås
Västra Götaland County
- Sahlgrenska University Hospital - Gothenburg
Östra Götaland
- Linköping University Hospital - Linköping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04722692
The ClinicalTrials.gov registry entry for NCT04722692 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Uppsala University, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Delayed SLND is the first listed.
NCT04722692 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, Dalarna County.
Frequently Asked Questions
What is clinical trial NCT04722692 about?
NCT04722692 is a clinical study titled "Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ". The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessary and should be avoided. This includes but is not limited to ...
What is the current status of trial NCT04722692?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2020-03-01. Estimated completion is 2027-12-30.
What conditions does trial NCT04722692 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms, DCIS, Sentinel Lymph Node.
What interventions are being tested in trial NCT04722692?
The interventions under investigation include: Delayed SLND (DIAGNOSTIC_TEST), Late SLND (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04722692?
This trial is sponsored by Uppsala University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04722692 being conducted?
This trial has 9 study locations across Texas, Dalarna County, Kronoberg County, Skåne County, Västmanland County. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.